dabigatran has been researched along with Disease Models, Animal in 58 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (5.17) | 29.6817 |
| 2010's | 46 (79.31) | 24.3611 |
| 2020's | 9 (15.52) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Akter, T; Annamalai, B; Obert, E; Rohrer, B; Simpson, KN | 1 |
| Demcsák, A; Jancsó, Z; Németh, BC; Pesei, ZG; Sahin-Tóth, M; Vajda, S | 1 |
| Callejas, S; Ceron, C; Cortes-Canteli, M; Fernandez-Nueda, I; Fuster, V; Ibanez, B; Jno-Charles, OC; Kruyer, A; Marcos-Diaz, A; Norris, EH; Richards, AT; Rodriguez, I; Ruiz-Cabello, J; Sanchez-Gonzalez, J; Strickland, S | 1 |
| Grammas, P; Iannucci, J; Johnson, SL; Seeram, NP | 1 |
| Cheng, W; Cheng, Y; Deng, Z; Huo, Y; Liao, Y; Liu, J; Xie, H; Zhang, M | 1 |
| Kimura, G; Kizawa, Y; Nagamoto, A; Nishimoto, Y; Takahashi, R; Ueda, K; Yoshino, K | 1 |
| Annaldas, S; Godugu, C; Saifi, MA | 1 |
| Brodsky, SV; Ivanov, I; Medipally, AK; Qaisar, S; Rovin, BH; Satoskar, AA; Xiao, M | 1 |
| Bar, A; Chlopicki, S; Enggaard, C; Hansen, PBL; Jasztal, A; Jensen, B; Kieronska-Rudek, A; Kij, A; Marczyk, B; Mateuszuk, L; Matyjaszczyk-Gwarda, K; Proniewski, B; Przyborowski, K; Tworzydlo, A; Walczak, M | 1 |
| Grottke, O; Honickel, M; Rossaint, R; Spronk, HM; Stoppe, C; Ten Cate, H; van Ryn, J | 1 |
| Braunschweig, T; Grottke, O; Honickel, M; Rossaint, R; Stoppe, C; Ten Cate, H | 1 |
| Dong, A; Morris, A; Mueller, P; Smyth, SS; Yang, F; Yang, L | 1 |
| Akman, N; Braunschweig, T; Grottke, O; Honickel, M; Rossaint, R; Schöchl, H; Schütt, K; Stoppe, C | 1 |
| Anstee, QM; Dhar, A; Goldin, RD; Levene, AP; Sadiq, F; Thursz, MR | 1 |
| Braunschweig, T; Grottke, O; Honickel, M; Rossaint, R; Schöchl, H | 1 |
| Bundgaard, H; Christophersen, LJ; Enevold, C; Goetze, JP; Høiby, N; Jensen, PØ; Lerche, CJ; Moser, C; Nielsen, PR; Thomsen, K | 1 |
| Feldmann, K; Fender, AC; Fischer, JW; Gerfer, S; Grandoch, M; Hartwig, S; Kohlmorgen, C; Lehr, S; Nagy, N; Valentin, B | 1 |
| Biessen, EA; Borissoff, JI; Daemen, MJ; Degen, JL; Esmon, CT; Hackeng, TM; Hamulyák, K; Heeneman, S; Leenders, P; Loubele, ST; Otten, JJ; Soehnlein, O; Spronk, HM; ten Cate, H; van Oerle, R; van Ryn, J; Weiler, H | 1 |
| Hoylaerts, MF; Missiakas, DM; Peetermans, M; Peetermans, WE; Schneewind, O; Van Aelst, LN; Vanassche, T; Verhaegen, J; Verhamme, P | 1 |
| Gong, GQ; He, GW; Jiang, ML; Li, YZ; Wang, XH; Xu, YG; Yang, WH; Yang, XZ; Zhou, Y | 1 |
| Ploen, R; Sun, L; Veltkamp, R; Zhou, W; Zorn, M | 1 |
| Brodsky, SV; Hebert, L; Nadasdy, G; Nadasdy, T; Qamri, Z; Rovin, B; Ryan, M; Satoskar, A; Ware, K; Wu, H | 1 |
| Abe, K; Deguchi, K; Ikeda, Y; Kono, S; Kurata, T; Omote, Y; Yamashita, T; Yunoki, T | 1 |
| Chintala, M; Keohane, C; Li, Q; Ni, W; O'Neill, K; Shang, J; Wang, M; Wei, H | 1 |
| Chantrathammachart, P; Hebbel, RP; Key, NS; Mackman, N; Mickelson, J; Monroe, DM; Pawlinski, R; Sparkenbaugh, EM; van Ryn, J | 1 |
| Grottke, O; Rossaint, R; Spronk, HM; van Ryn, J | 1 |
| Clemens, A; Kink-Eiband, M; Schurer, J; van Ryn, J | 1 |
| Levy, JH | 1 |
| Hale, SL; Kloner, RA | 1 |
| Brodsky, SV; Hebert, LA; Ivanov, I; Muni, N; Nadasdy, G; Nadasdy, T; Rovin, BH; Satoskar, AA; Vance, JC; Ware, KM | 1 |
| Dickneite, G; Doerr, B; Herzog, E; Kaspereit, FJ; Krege, W; Pragst, I; van Ryn, J | 1 |
| Hirose, Y; Inamasu, J; Tanoue, S; Toyama, H; Yamada, M | 1 |
| Grottke, O; Honickel, M; Rossaint, R; Tillmann, S; Treutler, S; van Ryn, J | 1 |
| Mracsko, E; Na, SY; van Ryn, J; Veltkamp, R | 1 |
| Narasimha Krishna, V; Rizk, DV; Saxena, N; Warnock, DG | 1 |
| Litzenburger, T; Nar, H; Ritter, M; Schiele, F; Seeliger, D; van Ryn, J | 1 |
| Chen, Q; Dai, P; Gong, G; Wang, S; Xu, Y; Zhu, Q | 1 |
| Berkhout, LC; de Boer, JD; de Stoppelaar, SF; Meijers, JC; Ottenhoff, R; Roelofs, JJ; van der Poll, T; van't Veer, C; Yang, J | 1 |
| Alexander, ET; Gilmour, SK; Goss, A; Hayes, CS; Minton, AR; Van Ryn, J | 1 |
| Bea, F; Cabbage, S; Ieronimakis, N; Preusch, MR; Reyes, M; Ricks, J; Rosenfeld, ME; van Ryn, J; Wijelath, ES | 1 |
| Braunschweig, T; Grottke, O; Honickel, M; Rossaint, R; Spronk, HM; Ten Cate, H; van Ryn, J | 1 |
| Gross, PL; Ni, R; Saldanha, LJ; Shaya, SA; Vaezzadeh, N; Zhou, J | 1 |
| Cave, G; Chauhan, A; Damitz, R; Harvey, M; Hunter, N; Wu, Z | 1 |
| Feuring, M; van Ryn, J | 1 |
| Dittmeier, M; Fluri, F; Kleinschnitz, C; Kraft, P; Schuhmann, MK; Wassmuth, K | 1 |
| Braun, D; Feinstein, DL; Givogri, MI; Kalinin, S; Marangoni, MN; Moyano, AL; Polak, P; Situ, A | 1 |
| Akaike, T; Date, T; Hano, H; Hongo, K; Ikegami, M; Ito, K; Kajimura, I; Kashiwagi, Y; Katoh, D; Kawai, M; Kimura, H; Kusakari, Y; Matsuo, S; Minai, K; Minamisawa, S; Morimoto, S; Nagoshi, T; Ogawa, K; Ogawa, T; Owada, M; Taniguchi, I; Yajima, J; Yamane, T; Yoshii, A; Yoshimura, M; Yoshino, T | 1 |
| Flores, JJ; Klebe, D; Krafft, PR; Lekic, T; McBride, DW; Rolland, WB; Zhang, JH | 1 |
| Lucas, J; Marco, P; Tarín, F | 1 |
| Becker, RC; Mackman, N | 1 |
| Akter, T; Bogatkevich, GS; Ludwicka-Bradley, A; Nietert, PJ; Silver, RM; van Ryn, J | 1 |
| De Nanteuil, G; Gloanec, P; Marx, I; Mennecier, P; Rupin, A; Vallez, MO; Verbeuren, TJ | 1 |
| Baumgarten, P; Bohmann, F; Foerch, C; Lindhoff-Last, E; Mittelbronn, M; Pfeilschifter, J; Pfeilschifter, W; Steinmetz, H | 1 |
| Bohmann, F; Foerch, C; Lindhoff-Last, E; Mirceska, A; Pfeilschifter, J; Pfeilschifter, W; Steinmetz, H | 1 |
| Gliem, M; Hartung, HP; Hermsen, D; Jander, S; van Rooijen, N | 1 |
| Mungall, D | 1 |
| Hauel, N; Priepke, H; Ries, UJ; Stassen, JM; Wienen, W | 1 |
4 review(s) available for dabigatran and Disease Models, Animal
| Article | Year |
|---|---|
Oral anticoagulants and risk of nephropathy.
Topics: Acute Kidney Injury; Administration, Oral; Animals; Anticoagulants; Dabigatran; Disease Models, Animal; Humans; Rats; Renal Insufficiency, Chronic; Risk Factors; Warfarin | 2015 |
The discovery of dabigatran etexilate for the treatment of venous thrombosis.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Dabigatran; Disease Models, Animal; Drug Interactions; Humans; Venous Thromboembolism; Warfarin | 2016 |
[New oral anticoagulants: molecular characteristics, mechanisms of action, pharmacokinetics and pharmacodynamics].
Topics: Administration, Oral; Animals; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dabigatran; Disease Models, Animal; Factor Xa Inhibitors; Forecasting; Hemostasis; Heparin, Low-Molecular-Weight; Humans; Pyridines; Quality of Life; Thrombin; Time Factors | 2008 |
BIBR-1048 Boehringer Ingelheim.
Topics: Animals; Benzimidazoles; Brain Ischemia; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dabigatran; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Prodrugs; Pyridines; Structure-Activity Relationship; Thromboembolism; Venous Thrombosis | 2002 |
54 other study(ies) available for dabigatran and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Dabigatran and Wet AMD, Results From Retinal Pigment Epithelial Cell Monolayers, the Mouse Model of Choroidal Neovascularization, and Patients From the Medicare Data Base.
Topics: Animals; Choroidal Neovascularization; Dabigatran; Disease Models, Animal; Epithelial Cells; Medicare; Mice; Retinal Pigments; Thrombin; United States; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2022 |
Preclinical testing of dabigatran in trypsin-dependent pancreatitis.
Topics: Animals; Dabigatran; Disease Models, Animal; Humans; Mice; Pancreas; Pancreatitis; Trypsin; Trypsinogen | 2022 |
Long-Term Dabigatran Treatment Delays Alzheimer's Disease Pathogenesis in the TgCRND8 Mouse Model.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Anticoagulants; Blood-Brain Barrier; Cerebral Cortex; Dabigatran; Disease Models, Animal; Female; Fibrin; Hemostasis; Hippocampus; Maze Learning; Memory; Mice; Mice, Transgenic; Neurodegenerative Diseases; Perfusion; Thrombosis | 2019 |
Inhibiting thrombin improves motor function and decreases oxidative stress in the LRRK2 transgenic Drosophila melanogaster model of Parkinson's disease.
Topics: Animals; Animals, Genetically Modified; Antithrombins; Dabigatran; Disease Models, Animal; Drosophila melanogaster; Female; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Locomotion; Male; Mutation; Oxidative Stress; Parkinson Disease; Thrombin | 2020 |
Dabigatran ameliorates airway smooth muscle remodeling in asthma by modulating Yes-associated protein.
Topics: Actins; Adaptor Proteins, Signal Transducing; Airway Remodeling; Animals; Asthma; Biomarkers; Cell Cycle Proteins; Dabigatran; Disease Models, Animal; Fluorescent Antibody Technique; Immunohistochemistry; Lung; Male; Mice; Muscle, Smooth; Ovalbumin; Signal Transduction; Stress Fibers; Thrombin; YAP-Signaling Proteins | 2020 |
[Inhibitory Effects of Dabigatran on Airway Inflammation Induced by Lipopolysaccharide in Mice].
Topics: Animals; Antithrombins; Asthma; Biomarkers; Bronchoalveolar Lavage Fluid; Chemokine CXCL1; Dabigatran; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Fluticasone; Inflammation; Inflammation Mediators; Lipopolysaccharides; Male; Mice, Inbred Strains; Osteopontin; Pulmonary Disease, Chronic Obstructive; Tumor Necrosis Factor-alpha | 2020 |
A direct thrombin inhibitor, dabigatran etexilate protects from renal fibrosis by inhibiting protease activated receptor-1.
Topics: Animals; Antithrombins; Collagen Type I; Dabigatran; Disease Models, Animal; Epithelial-Mesenchymal Transition; Fibrosis; Kidney; Kidney Diseases; Male; Mice; Oxidative Stress; Receptor, PAR-1; Signal Transduction; Snail Family Transcription Factors; Transforming Growth Factor beta; Ureteral Obstruction | 2021 |
Role of glomerular filtration rate-modifying drugs in the development of anticoagulant-related nephropathy.
Topics: Acute Kidney Injury; Albuterol; Animals; Antihypertensive Agents; Antithrombins; Bronchodilator Agents; Dabigatran; Disease Models, Animal; Enalapril; Glomerular Filtration Rate; Male; Nephrectomy; Rats; Rats, Sprague-Dawley | 2021 |
Thrombin Inhibition Prevents Endothelial Dysfunction and Reverses 20-HETE Overproduction without Affecting Blood Pressure in Angiotensin II-Induced Hypertension in Mice.
Topics: Angiotensin II; Animals; Antithrombins; Chromatography, Liquid; Dabigatran; Disease Models, Animal; Hydroxyeicosatetraenoic Acids; Hypertension; Intercellular Adhesion Molecule-1; Male; Mice; Nitric Oxide; Tandem Mass Spectrometry; Vascular Remodeling; von Willebrand Factor | 2021 |
Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Blood Coagulation; Dabigatran; Disease Models, Animal; Dose-Response Relationship, Drug; Hemorrhage; Hemostasis; Liver; Male; Sus scrofa | 2017 |
Reversing Dabigatran Anticoagulation with Prothrombin Complex Concentrate versus Idarucizumab as Part of Multimodal Hemostatic Intervention in an Animal Model of Polytrauma.
Topics: Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Disease Models, Animal; Hemorrhage; Hemostasis; Humans; Male; Multiple Trauma; Random Allocation; Swine | 2017 |
Direct thrombin inhibition with dabigatran attenuates pressure overload-induced cardiac fibrosis and dysfunction in mice.
Topics: Animals; Dabigatran; Disease Models, Animal; Fibrosis; Humans; Male; Mice; Myocardium; Thrombin | 2017 |
Reversal of dabigatran by intraosseous or intravenous idarucizumab in a porcine polytrauma model.
Topics: Administration, Intravenous; Animals; Antibodies, Monoclonal, Humanized; Antithrombins; Blood Coagulation; Dabigatran; Disease Models, Animal; Hemorrhage; Infusions, Intraosseous; Male; Multiple Trauma; Swine | 2018 |
Thrombin and factor Xa link the coagulation system with liver fibrosis.
Topics: Actins; Animals; Antithrombins; Blood Coagulation; Cell Line; Cell Shape; Dabigatran; Disease Models, Animal; Factor Xa; Factor Xa Inhibitors; Gene Expression; Hepatic Stellate Cells; Humans; Hydroxyproline; Liver Cirrhosis; Male; Mice, Inbred C57BL; Procollagen; Receptor, PAR-1; Rivaroxaban; Thrombin; Transforming Growth Factor beta | 2018 |
Evaluation of combined idarucizumab and prothrombin complex concentrate treatment for bleeding related to dabigatran in a lethal porcine model of double trauma.
Topics: Animals; Antibodies, Monoclonal, Humanized; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Disease Models, Animal; Hemodynamics; Hemorrhage; Male; Multiple Trauma; Swine; Thrombin | 2019 |
Adjunctive dabigatran therapy improves outcome of experimental left-sided Staphylococcus aureus endocarditis.
Topics: Animals; Anti-Bacterial Agents; Antithrombins; Aortic Valve; Bacterial Load; Chemotherapy, Adjuvant; Dabigatran; Disease Models, Animal; Drug Therapy, Combination; Endocarditis, Bacterial; Gentamicins; Humans; Male; Random Allocation; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus | 2019 |
Decreased M1 macrophage polarization in dabigatran-treated Ldlr-deficient mice: Implications for atherosclerosis and adipose tissue inflammation.
Topics: Adipose Tissue; Animals; Antithrombins; Aorta, Thoracic; Atherosclerosis; Dabigatran; Disease Models, Animal; Female; Flow Cytometry; Immunohistochemistry; Inflammation; Macrophage Activation; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout | 2019 |
Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Benzimidazoles; Blood Coagulation; Dabigatran; Disease Models, Animal; Disease Progression; Female; Hematopoiesis; Inflammation; Mice; Mice, Knockout; Neutrophils; Phenotype; Plaque, Atherosclerotic; Pyridines; Reactive Oxygen Species; Thrombin; Thrombosis | 2013 |
The role of staphylothrombin-mediated fibrin deposition in catheter-related Staphylococcus aureus infections.
Topics: Animals; Bacterial Adhesion; Bacterial Load; Benzimidazoles; beta-Alanine; Catheter-Related Infections; Central Venous Catheters; Coagulase; Dabigatran; Disease Models, Animal; Fibrin; Jugular Veins; Male; Mice; Mice, Inbred BALB C; Staphylococcal Infections; Thrombin | 2013 |
Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Disease Models, Animal; Mice; Prodrugs; Rabbits; Rats; RNA, Messenger; Thrombin; Thromboplastin; Thrombosis | 2013 |
Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia.
Topics: Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood-Brain Barrier; Cerebral Arteries; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Humans; Ischemia; Mice; Mice, Inbred C57BL; Rats; Stroke; Thrombolytic Therapy; Warfarin | 2013 |
Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats.
Topics: Acute Kidney Injury; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Disease Models, Animal; Hemorrhage; Kidney; Kidney Glomerulus; Male; Rats; Rats, Sprague-Dawley; Warfarin | 2014 |
Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Disease Models, Animal; Fibrinolytic Agents; Intracranial Hemorrhages; Male; Rats; Rats, Wistar; Stroke; Tissue Plasminogen Activator; Warfarin | 2014 |
A novel approach to assess the spontaneous gastrointestinal bleeding risk of antithrombotic agents using Apc(min/+) mice.
Topics: Age Factors; Animals; Benzimidazoles; Clopidogrel; Dabigatran; Disease Models, Animal; Drug Evaluation, Preclinical; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Genes, APC; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Pyrazoles; Pyridines; Pyridones; Risk Factors; Ticlopidine; Warfarin | 2014 |
Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Bone Marrow Transplantation; Dabigatran; Disease Models, Animal; Factor Xa; Factor Xa Inhibitors; Female; Immunoenzyme Techniques; Inflammation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Receptor, PAR-1; Receptor, PAR-2; Rivaroxaban; Thiophenes; Thrombin; Vascular Diseases | 2014 |
Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model.
Topics: Animals; Antidotes; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Disease Models, Animal; Factor VIIa; Factor Xa Inhibitors; Immunoglobulin Fab Fragments; Liver; Pyridines; Recombinant Proteins; Swine; Thrombelastography | 2014 |
Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation.
Topics: Animals; Benzimidazoles; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Disease Models, Animal; Hemorrhage; Humans; Pyridines; Rats; Rats, Wistar; Tail; Treatment Outcome | 2014 |
Role of coagulation factor concentrates for reversing dabigatran-related anticoagulation.
Topics: Animals; Benzimidazoles; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Disease Models, Animal; Hemorrhage; Humans; Pyridines | 2014 |
Dabigatran treatment: effects on infarct size and the no-reflow phenomenon in a model of acute myocardial ischemia/reperfusion.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Disease Models, Animal; Male; Myocardial Reperfusion Injury; No-Reflow Phenomenon; Rabbits | 2015 |
Oral warfarin and the thrombin inhibitor dabigatran increase blood pressure in rats: hidden danger of anticoagulants?
Topics: Acetylcysteine; Animals; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Pressure; Dabigatran; Disease Models, Animal; Dose-Response Relationship, Drug; Free Radical Scavengers; Nephrectomy; Pyrroles; Quinazolines; Rats; Receptor, PAR-1; Renal Insufficiency, Chronic; Vitamin K; Warfarin | 2015 |
Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model.
Topics: Animals; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Disease Models, Animal; Drug Combinations; Factor IX; Factor VII; Factor X; Female; Hemorrhage; Hemostatics; Prothrombin; Rabbits; Risk Assessment; Risk Factors; Thrombin; Time Factors; Venous Thrombosis | 2014 |
Does dabigatran increase the risk of delayed hematoma expansion in a rat model of collagenase-induced intracerebral hemorrhage?
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Collagenases; Dabigatran; Disease Models, Animal; Hematoma; Male; Rats; Rats, Wistar; Time Factors | 2015 |
Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Antifibrinolytic Agents; Antithrombins; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Coagulants; Dabigatran; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinogen; Infusions, Intravenous; Male; Multiple Trauma; Swine; Thrombin; Time Factors; Tranexamic Acid | 2015 |
Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to Dabigatran.
Topics: Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Bleeding Time; Blood Coagulation; Brain; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Hematoma; Mice; Thrombin Time; Warfarin | 2015 |
Structure-guided residence time optimization of a dabigatran reversal agent.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antibody Affinity; Crystallography, X-Ray; Dabigatran; Disease Models, Animal; Drug Design; Enzyme-Linked Immunosorbent Assay; Immunoglobulin Fab Fragments; Protein Conformation; Rats; Rats, Wistar; Thrombin Time | 2015 |
Design, Synthesis, and Biological Evaluation of Dabigatran Etexilate Mimics, a Novel Class of Thrombin Inhibitors.
Topics: Animals; Antithrombins; Binding Sites; Crystallography, X-Ray; Dabigatran; Disease Models, Animal; Drug Design; Hemorrhage; Humans; Ligands; Mice; Molecular Docking Simulation; Molecular Mimicry; Platelet Aggregation; Protein Binding; Protein Conformation; Rabbits; Rats; Rats, Sprague-Dawley; Risk Assessment; Structure-Activity Relationship; Thrombin; Venous Thrombosis | 2015 |
Effect of the oral thrombin inhibitor dabigatran on allergic lung inflammation induced by repeated house dust mite administration in mice.
Topics: Administration, Oral; Allergens; Animals; Antigens, Dermatophagoides; Antithrombin III; Antithrombins; Asthma; Blood Coagulation; Bronchoalveolar Lavage Fluid; Dabigatran; Dermatophagoides pteronyssinus; Disease Models, Animal; Female; Fibrin Fibrinogen Degradation Products; Humans; Inflammation Mediators; Lung; Male; Mice; Mice, Inbred C57BL; Peptide Hydrolases | 2015 |
Thrombin inhibition and cyclophosphamide synergistically block tumor progression and metastasis.
Topics: Animals; Antineoplastic Agents, Alkylating; Antithrombins; Cell Line, Tumor; Cell-Derived Microparticles; Cyclophosphamide; Dabigatran; Disease Models, Animal; Disease Progression; Drug Synergism; Female; Mice; Myeloid Cells; Neoplasm Metastasis; Neoplasms; Platelet Activation; Thrombin; Thromboplastin | 2015 |
Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice.
Topics: Age Factors; Animals; Antithrombins; Apolipoproteins E; Atherosclerosis; Dabigatran; Disease Models, Animal; Disease Progression; Flow Cytometry; Leukocyte Common Antigens; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oncostatin M; Sinus of Valsalva | 2015 |
Prothrombin Complex Concentrate Is Effective in Treating the Anticoagulant Effects of Dabigatran in a Porcine Polytrauma Model.
Topics: Animals; Antithrombins; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Disease Models, Animal; Femur; Hemorrhage; Liver; Male; Multiple Trauma; Sodium Chloride; Swine | 2015 |
Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism.
Topics: Animals; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Disease Models, Animal; Disease Progression; Embolization, Therapeutic; Female; Femoral Vein; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Lung; Mice; Mice, Inbred C57BL; Microscopy, Video; Pulmonary Embolism; Thrombosis; Venous Thromboembolism; Venous Thrombosis | 2016 |
Reversal of lipophilic weak bases using pH gradient acidic centre liposomes: demonstration of effect in dabigatran-induced anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Blood Coagulation; Dabigatran; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Hemorrhage; Hydrogen-Ion Concentration; Liposomes; Rabbits; Rats; Rats, Sprague-Dawley; Thrombin; Time Factors | 2016 |
Dabigatran Etexilate Reduces Thrombin-Induced Inflammation and Thrombus Formation in Experimental Ischemic Stroke.
Topics: Animals; Anticoagulants; Blood Coagulation; Blood-Brain Barrier; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Inflammation; Male; Rats, Wistar; Stroke; Thrombin; Thrombosis | 2016 |
Differential effects on glial activation by a direct versus an indirect thrombin inhibitor.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anticoagulants; Brain; Calcium-Binding Proteins; Dabigatran; Disease Models, Animal; Female; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microfilament Proteins; Mutation; Neuroglia; Peptide Fragments; Presenilin-1; Warfarin | 2016 |
Tissue thrombin is associated with the pathogenesis of dilated cardiomyopathy.
Topics: Animals; Antithrombins; Cardiomyopathy, Dilated; Case-Control Studies; Dabigatran; Disease Models, Animal; Humans; Mice; Thrombin | 2017 |
Dabigatran ameliorates post-haemorrhagic hydrocephalus development after germinal matrix haemorrhage in neonatal rat pups.
Topics: Administration, Intranasal; Animals; Animals, Newborn; Antithrombins; Dabigatran; Disease Models, Animal; Extracellular Matrix; Hydrocephalus; Injections, Intraperitoneal; Intracranial Hemorrhages; Maze Learning; Oligopeptides; Pyrroles; Quinazolines; Receptor, PAR-1; Rotarod Performance Test | 2017 |
DVT: a new era in anticoagulant therapy.
Topics: Animals; Anticoagulants; Benzimidazoles; Dabigatran; Disease Models, Animal; Factor Xa Inhibitors; Humans; Mice; Mice, Knockout; Morpholines; Pyridines; Rivaroxaban; Thiophenes; Thrombin; Venous Thrombosis | 2010 |
Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease.
Topics: Administration, Oral; Animals; Antithrombins; Benzimidazoles; beta-Alanine; Bleomycin; Dabigatran; Disease Models, Animal; Female; Lung Diseases, Interstitial; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Thrombin | 2011 |
S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; Biological Availability; Blood Coagulation Tests; Dabigatran; Disease Models, Animal; Dogs; Drug Evaluation; Humans; In Vitro Techniques; Inhibitory Concentration 50; Pyrazines; Pyridines; Pyrroles; Rats; Thrombin; Thrombosis | 2011 |
Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Drug Interactions; Fibrinolytic Agents; Mice; Mice, Inbred C57BL; Stroke; Tissue Plasminogen Activator; Warfarin | 2012 |
No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke.
Topics: Administration, Oral; Animals; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Male; Mice; Pyridines; Stroke; Treatment Outcome | 2012 |
Secondary intracerebral hemorrhage due to early initiation of oral anticoagulation after ischemic stroke: an experimental study in mice.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; Blood Coagulation; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Intracranial Embolism; Macrophages; Male; Mice; Mice, Inbred C57BL; Phenprocoumon; Pyridines; Risk Factors; Stroke; Time Factors | 2012 |
Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis.
Topics: Administration, Oral; Animals; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heparin; Hirudin Therapy; Injections, Intravenous; Male; Partial Thromboplastin Time; Prodrugs; Pyridines; Rabbits; Venous Thrombosis | 2007 |